Latest news with #GSKPlc
Business Recorder
01-08-2025
- Business
- Business Recorder
India's GlaxoSmithKline Pharma posts first revenue drop in over two years
Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, leading to its shares declining the most in nearly four months. The Indian unit of British drugmaker GSK Plc reported a 2% decline in its revenue from operations to 8.05 billion rupees ($92 million)for the first quarter ended June 30. GlaxoSmithKline Pharma said its performance during the quarter was 'below anticipated levels,' as it was hurt by 'external factors such as seasonal disruptions'. The stock slumped 5.5% after results and was on track for its worst day since early April. This is the company's first revenue drop since March 2023, when it grappled with lower prices of its key drugs due to the government's pricing cap. Separately, in May, it had a temporary production disruption due to a fire at one of its contract manufacturing facilities, but did not disclose whether there was a financial impact from it. Its quarterly profit climbed 12.5% on-year to 2.05 billion rupees as the company kept a tight lid on its expenses. Total expenses for the quarter dropped 5.2%.
Bloomberg
30-07-2025
- Business
- Bloomberg
GSK's Profit Outshines Estimates as Vaccines Keep Growing
GSK Plc reported better-than-expected profit in the second quarter, helped by vaccines including best-seller Shingrix for shingles. Earnings per share excluding some items rose to 46.5 pence, the UK drugmaker said Wednesday, higher than the 42.4 pence estimated by analysts surveyed by Bloomberg. GSK maintained its outlook for the year, saying results are likely to be at the top end of the range issued earlier this year.
Bloomberg
30-04-2025
- Business
- Bloomberg
GSK First-Quarter Profit Beats Estimates on Asthma, HIV Drugs
GSK Plc reported better-than-expected profit in the first quarter, with sales from its asthma and HIV drugs offsetting a lackluster vaccine performance. Earnings per share, excluding some items, were 44.9p, the UK drugmaker said Wednesday, higher than the 41p estimated by analysts surveyed by Bloomberg.
Bloomberg
17-04-2025
- Health
- Bloomberg
GSK's Blood Cancer Drug Approved in UK, Paving Return to Market
GSK Plc 's blood cancer drug Blenrep has won approval from the UK medicines regulator, opening the door to the return of a treatment that was withdrawn from the market about two years ago. In a boost for the British drugmaker, the UK is the first country to authorize Blenrep, in combination with other oncology drugs, for some patients with multiple myeloma, an incurable blood cancer, after they have received one previous treatment.
Bloomberg
16-04-2025
- Health
- Bloomberg
GSK Zantac Appeal Gets Tough Questions From Some Delaware Judges
Some Delaware Supreme Court justices signaled they may be skeptical of a bid by GSK Plc, Pfizer Inc. and other drugmakers to overturn a judge who allowed more than 80,000 lawsuits to proceed to trial over claims that the heartburn drug Zantac is linked to cancer. The state's highest court on Wednesday heard lawyers for the companies attack the findings of Superior Court Judge Vivian Medinilla, who ruled last year that scientific evidence backing the claims was legitimate and could be heard by juries. The companies contend Medinilla didn't property scrutinize the methodologies of certain expert witnesses, who found the medication could cause cancer if stored improperly.
